GlassScriptPhysician profile
Marc A Weiskopf
NPI 1922233360
$20,352.15
in general payments reported to CMS, 2019-2025
64 companies · $5,654 in 2025
The $5,654 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $424 · 2021: $908 · 2022: $2,708 · 2023: $3,500 · 2024: $5,556 · 2025: $5,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,689.52 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,303.25 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Biogen, INC. | $2,045.61 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $1,204.94 | 2023-2025 | |
| Ucb, INC. | $948.37 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Celgene Corporation | $854.42 | 2021-2025 | Zeposia |
| Mdd US Operations, LLC | $767.27 | 2019-2025 | Apokyn, Gocovri, Gocovri |
| Lilly USA, LLC | $747.33 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $719.79 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $702.81 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $654.83 | 2022-2025 | |
| Lundbeck LLC | $624.38 | 2023-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $591.96 | 2019-2025 | Crexont, Rytary, Ongentys |
| Acadia Pharmaceuticals INC | $467.13 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $452.45 | 2020-2025 | Xcopri |
| Emd Serono, INC. | $444.28 | 2019-2025 | Mavenclad, Mavenclad |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $367.48 | 2022-2025 | Ultomiris |
| Amgen INC. | $337.52 | 2019-2025 | Uplizna, Aimovig |
| Otsuka America Pharmaceutical, INC. | $335.75 | 2023-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $316.00 | 2022-2025 | Ingrezza, Ongentys |
| Vanda Pharmaceuticals INC. | $311.40 | 2024-2025 | Ponvory |
| Kyowa Kirin, INC. | $310.98 | 2020-2025 | Nourianz |
| Supernus Pharmaceuticals, INC. | $310.78 | 2019-2025 | Qelbree |
| Genzyme Corporation | $257.20 | 2019-2025 | |
| Argenx US, INC. | $235.93 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $222.90 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Allergan, INC. | $203.62 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.94 | 2023-2024 | Hyqvia, Gammagard |
| Tg Therapeutics, INC. | $157.89 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $152.28 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $150.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $146.51 | 2023-2025 | Wainua, Evusheld |
| Boston Scientific Corporation | $144.25 | 2024-2025 | General - Therapies, General - Pain Management |
| Merz Pharmaceuticals, LLC | $143.84 | 2024-2025 | Xeomin, Inbrija |
| Axsome Therapeutics, INC. | $142.60 | 2025 | Symbravo |
| Ge Healthcare | $113.15 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $97.91 | 2021 | |
| Acorda Therapeutics, INC | $96.64 | 2019-2023 | Inbrija |
| Sumitomo Pharma America, INC. | $86.71 | 2023-2024 | Aptiom |
| E.R. Squibb & Sons, L.L.C. | $80.32 | 2021-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $79.44 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.27 | 2022 | |
| Cala Health, INC. | $69.90 | 2023 | Cala Kiq, Cala Trio |
| Avion Pharmaceuticals | $63.20 | 2022-2023 | Dhivy |
| Tanabe Pharma America, INC. | $59.72 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $58.27 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $52.96 | 2024 | Onpattro |
| Catalyst Pharmaceuticals, INC. | $43.61 | 2019-2024 | |
| Greenwich Biosciences, INC. | $41.52 | 2019-2020 | |
| Banner Life Sciences, LLC | $39.83 | 2022 | |
| Vertical Pharmaceuticals, LLC | $34.91 | 2019 | |
| Neurelis, INC. | $33.83 | 2025 | Valtoco |
| Horizon Therapeutics Plc | $33.74 | 2022-2023 | Uplizna |
| Azurity Pharmaceuticals, INC. | $28.70 | 2025 | Horizant |
| Grifols USA, LLC | $24.92 | 2019 | |
| Janssen Biotech, INC. | $23.85 | 2025 | |
| Cycle Pharmaceuticals INC | $20.87 | 2025 | Bafiertam, Tascenso Odt |
| Insightec,INC | $20.38 | 2025 | Exablate |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Strongbridge US INC. | $18.73 | 2019 | |
| Life Molecular Imaging LTD | $16.71 | 2025 | Neuraceq |
| Jazz Pharmaceuticals INC. | $16.46 | 2024 | |
| Neuropace, INC. | $16.02 | 2024 | |
| Livanova USA, INC. | $14.90 | 2022 | |
| Shire North American Group INC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Weiskopf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.